A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies
Latest Information Update: 17 Jul 2024
At a glance
- Drugs EP 0042 (Primary) ; Antineoplastics
- Indications Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Ellipses Pharma
- 02 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 02 Jan 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Oct 2025.
- 23 Dec 2023 Planned number of patients changed from 63 to 75.